Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2007 1
2008 1
2013 1
2014 2
2015 3
2016 5
2017 3
2018 2
2019 1
2020 2
2021 4
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: ikeda t. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. Takada M, et al. Among authors: ikeda t. Breast Cancer Res Treat. 2023 Dec;202(3):485-496. doi: 10.1007/s10549-023-07099-4. Epub 2023 Sep 7. Breast Cancer Res Treat. 2023. PMID: 37676450 Free PMC article.
A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient.
Yatsuda Y, Hirose S, Ito Y, Onoda T, Sugiyama Y, Nagafuchi M, Suzuki H, Niisato Y, Tange Y, Ikeda T, Yamada T, Yamamoto Y, Ohyama Osawa M, Sakamoto N, Moriwaki T, Mizokami Y. Yatsuda Y, et al. Among authors: ikeda t. Intern Med. 2021 Apr 1;60(7):1011-1017. doi: 10.2169/internalmedicine.5893-20. Epub 2020 Nov 9. Intern Med. 2021. PMID: 33162479 Free PMC article.
Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases.
Hirose S, Enami C, Kawamatsu N, Ito Y, Onoda T, Sugiyama Y, Suzuki H, Nagafuchi M, Ikeda T, Niisato Y, Yamada T, Yamamoto Y, Moriwaki T, Suzuki H. Hirose S, et al. Among authors: ikeda t. Int Cancer Conf J. 2021 Aug 29;11(1):17-22. doi: 10.1007/s13691-021-00507-w. eCollection 2022 Jan. Int Cancer Conf J. 2021. PMID: 35127316 Free PMC article.
26 results